NASDAQ:IVF

INVO Fertility Q3 2026 Earnings Results & Report

INVO Fertility logo
$1.76 0.00 (0.00%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.76 0.00 (0.00%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

INVO Fertility reported Q3 2026 earnings on November 16, 2026. The company reported EPS of -$2.44, while revenue was $2.22 million.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens

INVO Fertility EPS Results

Actual EPS
-$2.44
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

INVO Fertility Revenue Results

Actual Revenue
$2.22 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

INVO Fertility Q3 2026 Earnings FAQ

INVO Fertility (NASDAQ:IVF) reported earnings of -$2.44 per share for Q3 2026. The report was announced on Monday, November 16, 2026.

INVO Fertility reported revenue of $2.22 million for Q3 2026.

INVO Fertility Earnings Headlines

Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
See More INVO Fertility Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like INVO Fertility? Sign up for Earnings360's daily newsletter to receive timely earnings updates on INVO Fertility and other key companies, straight to your email.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a fertility-care company that develops and provides treatments for people seeking to build a family. Its offerings include fertility services through its clinics and the INVOcell® system, a device and procedure that allows fertilization and early embryo development to take place inside the patient’s body.

The company’s approach is an alternative to conventional in vitro fertilization, while also offering fertility care through its clinic operations. INVO Fertility has pursued growth by expanding its network of fertility centers in the United States and by making its technology available in international markets.

Previously known as INVO Bioscience, the company adopted the INVO Fertility name to reflect its broader focus on fertility services as well as reproductive technology.

View INVO Fertility Profile